Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunocore Holdings plcIMCR · Entity 4544 | CHIEF FINANCIAL OFFICER | February 16, 2024 | February 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunocore Holdings plc
Report date February 16, 2024 · Filed February 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.50 · Expires 2034-02-15 | Direct | 66,746 |
Reported balance
After 2024-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-16 · Grant · Acquired 66,746 · Balance 66,746 F1: 25% of the shares subject to the option award shall vest on February 16, 2025, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option award shall vest on February 16, 2025, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date January 28, 2020 · Filed January 29, 2020
Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2028-08-07 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-28 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-28 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2024 Filed Feb 21, 2024 21:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantEmployee Share Option (Right to Buy) · Derivative | 66,746 | $0.00 Strike: $70.50 | $0.00 |
DisclosureSEC source: 0001415889-24-004592 · form4-02212024_040224.xml · derivative · entry 1 Di Donato Brian · CIK 0001766498 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,746 Underlying: Ordinary Shares · 66,746 shares Expires 2034-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option award shall vest on February 16, 2025, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:12 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.29 | Not disclosed |
DisclosureSEC source: 0001562180-20-000668 · primarydocument.xml · derivative · entry 2 Di Donato Brian · CIK 0001766498 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2029-02-11 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:12 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 200,000 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001562180-20-000668 · primarydocument.xml · derivative · entry 1 Di Donato Brian · CIK 0001766498 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2028-08-07 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| February 11, 2019 Filed Feb 11, 2019 18:25 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantStock Option (Right to buy) · Derivative | 500,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-19-009103 · doc4.xml · derivative · entry 1 Di Donato Brian · CIK 0001766498 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-02-11 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.